Compounds > drosocin
Page last updated: 2024-11-12

drosocin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

drosocin: amino acid sequence given in first source for drosocin and its precursor; GenBank Z21942 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16131048
CHEMBL ID217215
MeSH IDM0218898

Synonyms (7)

Synonym
149924-99-2
l-valine, glycyl-l-lysyl-l-prolyl-l-arginyl-l-prolyl-l-tyrosyl-l-seryl-l-prolyl-l-arginyl-l-prolyl-l-threonyl-l-seryl-l-histidyl-l-prolyl-l-arginyl-l-prolyl-l-isoleucyl-l-arginyl-
glycyl-l-lysyl-l-prolyl-l-arginyl-l-prolyl-l-tyrosyl-l-seryl-l-prolyl-l-arginyl-l-prolyl-l-threonyl-l-seryl-l-histidyl-l-prolyl-l-arginyl-l-prolyl-l-isoleucyl-l-arginyl-l-valine
gkprpysprptshprpirv
drosocin
CHEMBL217215
DTXSID50164429

Research Excerpts

Overview

Drosocin is a cationic 19 amino acid peptide secreted by Drosophila in response to septic injury.

ExcerptReferenceRelevance
"Drosocin is a 19-mer, cationic antimicrobial peptide from Drosophila melanogaster. "( Evaluation of the antibacterial spectrum of drosocin analogues.
Bikker, FJ; de Visser, PC; de Vries-van de Ruit, AM; Kaman-van Zanten, WE; Mars-Groenendijk, RH; Noort, D; van Hooft, PA; Voskamp-Visser, I, 2006)		2.04
"Drosocin is a cationic 19 amino acid peptide secreted by Drosophila in response to septic injury. "( Conformational studies by NMR of the antimicrobial peptide, drosocin, and its non-glycosylated derivative: effects of glycosylation on solution conformation.
Craik, DJ; Hoffmann, R; McManus, AM; Otvos, L, 1999)		1.99
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID511695Cytotoxicity against human CEM-SS cells infected with HIV1 3B after 6 days by XTT assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.
AID94139Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Klebsiella pneumoniae 792002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues.
AID198004Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Staphylococcus enteritidis D52002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues.
AID94138Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Klebsiella pneumoniae 222002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues.
AID1197604Antimicrobial activity against Escherichia coli ATCC 25922 by broth microdilution assay2015European journal of medicinal chemistry, Mar-06, Volume: 92Understanding the importance of glycosylated threonine and stereospecific action of Drosocin, a Proline rich antimicrobial peptide.
AID9221Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues.
AID64242Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Escherichia coli ML-352002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues.
AID1197607Antimicrobial activity against Salmonella typhimurium ATCC 14028 by broth microdilution assay2015European journal of medicinal chemistry, Mar-06, Volume: 92Understanding the importance of glycosylated threonine and stereospecific action of Drosocin, a Proline rich antimicrobial peptide.
AID1197605Antimicrobial activity against Escherichia coli ATCC 11775 by broth microdilution assay2015European journal of medicinal chemistry, Mar-06, Volume: 92Understanding the importance of glycosylated threonine and stereospecific action of Drosocin, a Proline rich antimicrobial peptide.
AID482395Cytotoxicity against human SH-SY5Y cells at 600 ug/ml after 24 hrs by MTT assay2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Oncocin (VDKPPYLPRPRPPRRIYNR-NH2): a novel antibacterial peptide optimized against gram-negative human pathogens.
AID198005Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 h of incubation at 37 C in Mueller-Hinton broth against Staphylococcus enteritidis PD12002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues.
AID64223Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Escherichia coli D222002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues.
AID511694Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.
AID244840Minimum inhibitory concentration against Escherichia coli ATCC 11775 strain2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Biological evaluation of Tyr6 and Ser7 modified drosocin analogues.
AID64219Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Escherichia coli D212002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues.
AID64243Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Escherichia coli O18:K1:H72002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues.
AID1197606Antimicrobial activity against Escherichia coli ATCC 35218 by broth microdilution assay2015European journal of medicinal chemistry, Mar-06, Volume: 92Understanding the importance of glycosylated threonine and stereospecific action of Drosocin, a Proline rich antimicrobial peptide.
AID150919Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Pseudomonas aeruginosa ATCC 278532002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues.
AID249731Percent of intact peptide after 8 hr of digestion in 25% human serum2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Biological evaluation of Tyr6 and Ser7 modified drosocin analogues.
AID482394Cytotoxicity against human HeLa cells at 600 ug/ml after 24 hrs by MTT assay2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Oncocin (VDKPPYLPRPRPPRRIYNR-NH2): a novel antibacterial peptide optimized against gram-negative human pathogens.
AID1197608Antimicrobial activity against Salmonella typhi Vi+ by broth microdilution assay2015European journal of medicinal chemistry, Mar-06, Volume: 92Understanding the importance of glycosylated threonine and stereospecific action of Drosocin, a Proline rich antimicrobial peptide.
AID197876Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Staphylococcus aureus G2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues.
AID198329Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Salmonella Typhimurium ATCC 140282002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues.
AID64216Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Escherichia coli ATCC 259222002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues.
AID198008Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Staphylococcus epidermidis 42002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (24.32)18.2507
2000's11 (29.73)29.6817
2010's14 (37.84)24.3611
2020's3 (8.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.31 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other35 (94.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
hydroxyproline
Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.. hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.		7.46204-hydroxyproline;
L-alpha-amino acid zwitterion		human metabolite;
mouse metabolite;
plant metabolite
serine
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.		2.0210L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
tyrosine
Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.		2.0210amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
histidine
Histidine: An essential amino acid that is required for the production of HISTAMINE.. L-histidine : The L-enantiomer of the amino acid histidine.. histidine : An alpha-amino acid that is propanoic acid bearing an amino substituent at position 2 and a 1H-imidazol-4-yl group at position 3.		210amino acid zwitterion;
histidine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
threonine
Threonine: An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.. threonine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group.		7.1110amino acid zwitterion;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
threonine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
pyrrolidonecarboxylic acid
Pyrrolidonecarboxylic Acid: A cyclized derivative of L-GLUTAMIC ACID. Elevated blood levels may be associated with problems of GLUTAMINE or GLUTATHIONE metabolism.. 5-oxo-L-proline : An optically active form of 5-oxoproline having L-configuration.		2.15105-oxoproline;
L-proline derivative;
non-proteinogenic L-alpha-amino acid		algal metabolite
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		2.0510azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
proline
Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.		7.7430amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
(4-24)-ply(a)
peptide-Gly-Leu-amide: 21-amino acid peptide from skin secretion of Xenopus laevis; amino acid sequence given in first source		2.0510
pyrrhocoricin protein, pyrrhocoris apterus
pyrrhocoricin protein, Pyrrhocoris apterus: a 20-residue proline-rich peptide carrying an O-glycosylated substitution; from the sap-sucking bug Pyrrhocoris apterus; active against Gram-negative bacteria; amino acid sequence given in first source		2.6930
ceca1 protein, drosophila
[no description available]		4.3860
apidaecin ib
apidaecin: isolated from lymph fluid of honeybee; amino acid sequence given in first source; not antibiotic, since it does not come from microorganism		4.2450
parasin i
[no description available]		2.0510
ropocamptide
ropocamptide: from granulocytes & keratinocytes, precursor to cathelicidins; MW 16-18 kDa; GenBank AJ224927 (eCATH-1). cathelicidin : A group of small, cationic polypeptides (consisting of 12-97 amino acids) that are found in humans and other species, including farm animals (E.g. cattle, horses, pigs, sheep etc). They show a broad spectrum of antimicrobial activity against bacteria, enveloped viruses and fungi.		2.0510
spinigerin
spinigerin: antimicrobial peptide isolated from the fungus-growing termite Pseudacanthotermes spiniger (heterometabole insect, Isoptera); GenBank P82357		2.0510
isracidin
isracidin: the N-terminal segment (1-23) of alpha(S1)-casein B; amino acid sequence given in first source		2.0510
oncocin
oncocin: a synthetic peptide		2.4820
lycotoxin i
lycotoxin I: an antimicrobial peptide from the venom of Wolf spider, Lycosa carolinensis; amino acid sequence in first source		2.0510
melectin
melectin: isolated from the venom of the cleptoparasitic bee Melecta albifrons		2.0510
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		2.1110
indolicidin
[no description available]		3.3110
ConditionIndicatedRelationship StrengthStudiesTrials
Extravascular Hemolysis
[description not available]		02.9640
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		02.9640
Degenerative Diseases, Central Nervous System
[description not available]		02.1510
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		02.1510
Neurodegenerative Diseases
Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.		02.1510
Plasmodium falciparum Malaria
[description not available]		02.2110
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.2110
E coli Infections
[description not available]		02.7330
Infections, Klebsiella
[description not available]		02.110
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		02.7330
Klebsiella Infections
Infections with bacteria of the genus KLEBSIELLA.		02.110
Bacterial Disease
[description not available]		01.9810
Fungal Diseases
[description not available]		01.9810
Bacterial Infections
Infections by bacteria, general or unspecified.		01.9810
Mycoses
Diseases caused by FUNGI.		01.9810